Results 31 to 40 of about 52,949 (209)

Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck [PDF]

, 2008
Introduction: Gefitinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces growth arrest in squamous cancer cell carcinoma of head and neck (SCCHN) cell lines mainly by blocking cells in G1 and preventing them ...
Romano, Carmela
core   +1 more source

Genotoxicity and in vitro investigation of Gefitinib-loaded polycaprolactone fabricated nanoparticles for anticancer activity against NCI-H460 cell lines

Journal of Experimental Nanoscience, 2022
For non-small cell lung cancer (NSCLC) treatment, a BCS class II drug, Gefitinib, was widely used. Due to poor bioavailability, uncontrollable drug release, Gefitinib witnessed side effects.
Sankha Bhattacharya
doaj   +1 more source

Inhibition of the mitochondria-shaping protein Opa1 restores sensitivity to Gefitinib in a lung adenocarcinomaresistant cell line

Cell Death and Disease, 2023
Drug resistance limits the efficacy of chemotherapy and targeted cancer treatments, calling for the identification of druggable targets to overcome it.
Masafumi Noguchi, Susumu Kohno, Anna Pellattiero, Yukino Machida, Keitaro Shibata, Norihito Shintani, Takashi Kohno, Noriko Gotoh, Chiaki Takahashi, Atsushi Hirao, Luca Scorrano, Atsuko Kasahara   +11 more
doaj   +1 more source

Knockdown of translocase of inner mitochondrial membrane 8A enhances gefitinib sensitivity to lung cancer cell line PC-9 [PDF]

Jichu yixue yu linchuang
Objective To explore the alteration and function of TIMM8A during gefitinib-induced growth inhibition of lung cancer cell line PC-9. Methods TIMM8A siRNA transfection experiment was used to inhibit the expression of TIMM8A in PC-9 and gefitinib resistant
CHEN Lei,REN Weihao,WANG Lide
doaj   +1 more source

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

BMC Cancer, 2020
Background The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non ...
Wenxiu Yao, Liyang Wang, Huan Huang, Xin Li, Pinjia Wang, Kun Mi, Jia Cheng, Huifen Liu, Cuirong Gu, Lingxiao Huang, Jianming Huang   +10 more
doaj   +1 more source

Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS‐dependent apoptosis and ferroptosis

Kaohsiung Journal of Medical Sciences, 2023
The application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, has shifted lung cancer treatment from empirical chemotherapy to targeted molecular therapy. However, acquired drug resistance is inevitable in
Xiang‐Yu Lai, Yu‐Mei Shi, Ming‐Ming Zhou   +2 more
doaj   +1 more source

Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib

Chinese Journal of Lung Cancer, 2015
Background and objective Nowadays the secondary resistance of gefitinib in the treatment of lung adenocarcinoma is an outstanding problem. This research is to explore whether the gefitinib secondary resistance can be induced by gefitinib, to explore ...
Qilong WANG, Min LI, Chengping HU
doaj   +1 more source

Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer

Brazilian Journal of Medical and Biological Research, 2017
Non-small-cell lung cancer (NSCLC) patients who experience brain metastases are usually associated with poor prognostic outcomes. This retrospective study proposed to assess whether bevacizumab or gefitinib can be used to improve the effectiveness of ...
R.F. Yang, B. Yu, R.Q. Zhang, X.H. Wang, C. Li, P. Wang, Y. Zhang, B. Han, X.X. Gao, L. Zhang, Z.M. Jiang   +10 more
doaj   +1 more source

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Chinese Journal of Lung Cancer, 2022
Background and objective Acquired and primary resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is still the bottleneck of clinical treatment of advanced non-small cell lung cancer (NSCLC).
Lin HUANG, Mei HOU, Jiewei LIU, Yang LI, Wang SHEN, Qinghua ZHOU   +5 more
doaj   +1 more source

Cellular targets of gefitinib

, 2005
Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear.
Müller, Stefan, Klebl, Bert, Wissing, Josef, Daub, Henrik, Brehmer, Dirk, Greff, Zoltán, Godl, Klaus, Kurtenbach, Alexander, Kéri, György, Weber, Martina, Blencke, Stephanie, Cotten, Matt   +11 more
core   +7 more sources